Farha Samar
Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic.
Cleve Clin J Med. 2020 May 11. doi: 10.3949/ccjm.87a.ccc021.
Pulmonary hypertension (PH) is a pulmonary vascular disease characterized by pulmonary arterial remodeling and vasoconstriction leading to elevated pulmonary artery pressure and, ultimately, right heart failure. So far, few cases of COVID-19 disease in patients with PH have been reported. Caution is warranted in interpreting this observation as data are evolving and several factors may influence the number of reported cases of PH and COVID-19. Social distancing and quarantine could play a role, especially for patients with chronic diseases who might be more vigilant of their potential for respiratory infection. In addition, PH is a rare disease, and because testing is not universal, we could be underestimating the number of cases. Other hypothetical factors to consider are the underlying pathophysiology of PH and the medications used to treat PH and their implications in COVID-19.
肺动脉高压（PH）是一种以肺动脉重塑和血管收缩为特征的肺血管疾病，可导致肺动脉压力升高，最终引发右心衰竭。到目前为止，PH患者中COVID-19疾病的病例报道较少。鉴于数据仍在不断变化，且有几个因素可能影响PH和COVID-19报告病例数，因此在解读这一观察结果时需谨慎。社交距离和隔离可能起到了作用，尤其是对于那些可能对呼吸道感染可能性更为警惕的慢性病患者。此外，PH是一种罕见疾病，由于检测并非普遍开展，我们可能低估了病例数。其他需要考虑的假设因素包括PH的潜在病理生理学、用于治疗PH的药物及其对COVID-19的影响。
